🌍·2h agoIndustry
Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Publisher
B
Benitec Biopharma
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on benitec.com
Leave the platform to read the original full article on the publisher site.
Source: Benitec Biopharma
Scope: Industry
Related coverage
More related coverage
BioLineRx·2h ago
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
Petros Pharmaceuticals·13h ago
Shop — Petro's Chili & Chips™
Eledon Pharmaceuticals·17h ago
MAb-based immunosuppressant supports crucial diabetes cell transplants
Adial Pharmaceuticals·1d ago